### Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

	Edga			01100	0 1110					
Form 4	HERAPEUTICS INC									
March 11, 2	ЛЛ						OMB AF	PROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Check this box if no longer Section 16. Check this box if no longer subject to Section 16. Check this box if no longer Section 16. Section 16. Sect										
(Print or Type	Responses)									
1. Name and A Do Hung	Symbol	MICUS THERAPEUTICS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (Middle)					Director		Owner		
C/O AMIC	(Month/Day/Year) 03/07/2014	-				XOfficer (give titleOther (specify below) below) Sr Vice President Discovery				
			d(Month/Day/Year) Applicable Line _X_Form filed					Joint/Group Filing(Check One Reporting Person More than One Reporting		
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								v Owned		
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Da (Month/Day/Year) Execut any (Month	emed 3. ion Date, if Transacti	4. Securitie for(A) or Disp (Instr. 3, 4	es Acqui posed of	ired	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Common		Code V	Amount	(D)	Price \$	(Instr. 3 and 4)				
stock	03/07/2014	D	68,418		2.32 (1)	1,331,361	D			
Common stock	03/10/2014	D	108,018	D	\$ 2.28 (2)	1,223,343	D			
Common stock	03/11/2014	D	121,642	D	\$ 2.22 (3)	1,101,701	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transactio	5. Mumber	6. Date Exercised Expiration D		7. Titl Amou		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security	(Monul/Day/Tear)	(Month/Day/Year)	Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/ e		Under Securi	lying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Do Hung C/O AMICUS THERAPEUTICS CRANBURY, NJ 08512			Sr Vice President Discovery				
Signatures							

/s/ Hung Do	03/11/2014		
**Signature of	Date		

Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$2.30 to \$2.42. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange (1) Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$2.25 to \$2.33. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange (2) Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this (3) line range from \$2.20 to \$2.28. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

### Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

#### **Remarks:**

Shares sold solely to meet tax obligations arising for Dr. Do in conjunction with the sale of Callidus Biopharma to Amicus The

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.